To Wall Street, a new bidding war puts Alkermes in a tough spot

Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying significantly more than it had hoped.

Jacob Bell Member since October 18, 2023

Loading + Follow Following